Vincristine (Oncovin)

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established (work in progress)

Non-Hodgkin lymphoma

Diseases for which it is used

Diseases for which it was used

Notable side effects

Neuropathy ^[3]

Patient drug information

History of changes in FDA indication

1963-07-10: Initial FDA approval
2014-08-05 (oldest label available at Drugs @ FDA): Indicated in acute leukemia. It has also been shown to be useful in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor. (No supporting studies are cited)

History of changes in EMA indication

1995-04-12: EURD

History of changes in PMDA indication

2013-03-25: New additional indication and a new dosage for the treatment of pheochromocytoma.

Also known as

Generic names: LCR, leurocristine, VCR, vincristine sulfate
Brand names:

Synonyms
Alcrist	Biocrist	Biocrystin	Cellcristin	Citomid	Crivosin	Farmistin CS	Fauldvincri
Krebin	Kyocristine	Nevexitin	Oncovin	Onkocristin	Pericristine	Pharmacristine	Tecnocris
Vincasar	Vinces	Vincosid	Vincran	Vincrex	Vincrifil	Vincrin	Vincrisin
Vincrisol	Vincristin	Vincristina	Vincristinesulfaat	Vincristinsulfat	Vincristinum	Vincrisul	Vinracin
Vinracine	Vinstin	Vintec

References

↑ ^1.0 ^1.1 Vincristine (Oncovin) package insert
↑ Vincristine (Oncovin) package insert (locally hosted backup)
↑ Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article contains dosing details in manuscript PubMed
↑ Vincristine (Oncovin) patient drug information (Chemocare)
↑ Vincristine (Oncovin) patient drug information (UpToDate)

[insert-1] 1.0 ^1.1 Vincristine (Oncovin) package insert

[2] Vincristine (Oncovin) package insert (locally hosted backup)

[3] Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article contains dosing details in manuscript PubMed

[4] Vincristine (Oncovin) patient drug information (Chemocare)

[5] Vincristine (Oncovin) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

[5]